SUNZEN Stock Overview
Engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sunzen Biotech Berhad Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RM 0.32 |
| 52 Week High | RM 0.40 |
| 52 Week Low | RM 0.22 |
| Beta | 1.85 |
| 1 Month Change | 1.59% |
| 3 Month Change | -1.54% |
| 1 Year Change | 8.47% |
| 3 Year Change | 48.84% |
| 5 Year Change | 178.26% |
| Change since IPO | 71.43% |
Recent News & Updates
Sunzen Biotech Berhad's (KLSE:SUNZEN) CEO Looks Due For A Compensation Raise
Dec 12
Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations
Nov 07Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit
Oct 15Recent updates
Sunzen Biotech Berhad's (KLSE:SUNZEN) CEO Looks Due For A Compensation Raise
Dec 12Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations
Nov 07Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit
Oct 15Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher
Aug 06If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity
May 25Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking
May 24Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price
Apr 22Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You
Nov 16Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?
Mar 26Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?
Dec 10
Shareholder Returns
| SUNZEN | MY Personal Products | MY Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -0.2% |
| 1Y | 8.5% | -12.7% | 10.1% |
Return vs Industry: SUNZEN exceeded the MY Personal Products industry which returned -12.7% over the past year.
Return vs Market: SUNZEN underperformed the MY Market which returned 10.1% over the past year.
Price Volatility
| SUNZEN volatility | |
|---|---|
| SUNZEN Average Weekly Movement | 3.1% |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in MY Market | 10.4% |
| 10% least volatile stocks in MY Market | 2.5% |
Stable Share Price: SUNZEN has not had significant price volatility in the past 3 months compared to the MY market.
Volatility Over Time: SUNZEN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Yek Teo | www.sunzen.com.my |
Sunzen Biotech Berhad engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. It operates through three segments: Animal Health, Human Health, and Loan Financing. The company provides veterinary machines, pharmaceutical, chemical products, animal health products and equipment, laboratory services, and beauty and cosmetic products.
Sunzen Biotech Berhad Fundamentals Summary
| SUNZEN fundamental statistics | |
|---|---|
| Market cap | RM 248.89m |
| Earnings (TTM) | RM 6.03m |
| Revenue (TTM) | RM 95.12m |
41.3x
P/E Ratio2.6x
P/S RatioIs SUNZEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUNZEN income statement (TTM) | |
|---|---|
| Revenue | RM 95.12m |
| Cost of Revenue | RM 69.57m |
| Gross Profit | RM 25.55m |
| Other Expenses | RM 19.53m |
| Earnings | RM 6.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0077 |
| Gross Margin | 26.86% |
| Net Profit Margin | 6.34% |
| Debt/Equity Ratio | 4.3% |
How did SUNZEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 10:47 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sunzen Biotech Berhad is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|